| Cramer, Steven C |
| Recruiting | N/A | 60 | US | HandyMotion Treatment Program | TRCare, Inc., California Rehabilitation Institute | Cerebral Stroke, Traumatic Brain Injury, Spinal Cord Injuries | 05/25 | 05/25 | | |
| Bhatia, Nitin |
| Recruiting | N/A | 80 | US | DEXA-C Cervical Interbody System | Aurora Spine and Pain | Degenerative Disc Disease | 02/25 | 12/25 | | |
| Kim, Richard |
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer |
|
|
| Recruiting | 3 | 480 | US | Glufosfamide, Fluorouracil, 5-FU | Eleison Pharmaceuticals LLC. | Metastatic Pancreatic Adenocarcinoma | 06/26 | 12/26 | | |
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen | Lupus Erythematosus, Systemic | 09/25 | 03/26 | | |
NCT02829918: Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers |
|
|
| Completed | 2 | 54 | US | Nivolumab, OPDIVO | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Biliary Tract Cancer, Biliary Tract Neoplasms | 03/19 | 05/23 | | |
NCT06553885: Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC |
|
|
| Not yet recruiting | 2 | 40 | US | Enfortumab Vedotin, PADCEV | H. Lee Moffitt Cancer Center and Research Institute, Astellas Pharma Inc | Metastatic Colorectal Cancer, Hepatocellular Carcinoma | 09/29 | 09/29 | | |
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 80 | Europe, US | LSTA1, certepetide, CEND-1, Durvalumab, Imfinzi, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo | Lisata Therapeutics, Inc. | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 03/26 | 03/26 | | |
NCT05108428: Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma |
|
|
| Active, not recruiting | 1 | 20 | US | Capecitabine, Xeloda, Radiation Therapy, FOLFOX regimen | H. Lee Moffitt Cancer Center and Research Institute, Viewray Inc., Natera, Inc. | Rectal Adenocarcinoma | 10/23 | 10/26 | | |
| Recruiting | 1 | 275 | Europe, US | SGN-EGFRd2 | Seagen Inc. | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma | 07/27 | 09/28 | | |
NCT04956744: A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis |
|
|
| Recruiting | 1 | 30 | US | IMS001 | ImStem Biotechnology, Rho, Inc. | Multiple Sclerosis | 12/27 | 12/27 | | |
| Duma, Christopher |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
| Loudon, William |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
NCT04540445: Utility of Pupillary Metrics in Diagnosis and Management of Concussion in Children |
|
|
| Recruiting | N/A | 130 | US | Pupillary Assessment, NeurOptics PLR-3000, NeurOptics NPi®-200 | Children's Hospital of Orange County, NeurOptics Inc. | Brain Concussion, Reflex, Pupillary, Post-Concussion Syndrome, Brain Injuries, Traumatic | 09/22 | 12/22 | | |
| Bota, Daniela |
NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme |
|
|
| Active, not recruiting | 2 | 84 | US | ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV | Epitopoietic Research Corporation, University of California, Irvine | Glioblastoma, Gliosarcoma | 03/23 | 03/23 | | |
|
NCT03450850: Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma |
|
|
| Active, not recruiting | 2 | 34 | US | NOVOTTF-200A | Daniela A. Bota, NovoCure Ltd. | Astrocytoma, Grade III | 09/23 | 09/24 | | |
| Active, not recruiting | 2 | 210 | Europe, US | Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine | CNS Pharmaceuticals, Inc., Worldwide Clinical Trials | Glioblastoma Multiforme, Adult | 12/24 | 03/25 | | |
|
|
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas |
|
|
| Recruiting | 2 | 124 | US | Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation | Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation | 01/26 | 01/28 | | |
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study) |
|
|
| Recruiting | 2 | 112 | US | Tirabrutinib, ONO-4059 | Ono Pharmaceutical Co. Ltd | Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma | 03/27 | 03/27 | | |
NCT04520139: Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT |
|
|
| Not yet recruiting | 1/2 | 102 | NA | N-Acetyl-Cysteine, NAC Sustain, NAC, Placebo | University of California, Irvine, Jarrow Formulas Inc | Ovarian Cancer, Cognitive Impairment | 12/25 | 12/26 | | |
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects |
|
|
| Recruiting | 1/2 | 98 | US | VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine | VBI Vaccines Inc. | Glioblastoma Multiforme | 07/25 | 08/25 | | |
NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 53 | US | ABM-1310, ABM1310, Cobimetinib, Cotellic® | ABM Therapeutics Corporation | Advanced Solid Tumor, BRAF V600 Mutation | 04/24 | 04/24 | | |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
| Lin, Jack |
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
|
|
| Recruiting | 1/2 | 40 | US | NRTX-1001, GABA-secreting interneurons, Sham Comparator | Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM) | Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis | 05/25 | 05/26 | | |
| Sender, Leonard S |
NCT06710288: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
|
|
| Recruiting | 2 | 20 | US | Gemcitabine, gemcitabine hydrocholoride, Gemzar, N-803, M-CENK, Autologous Memory Cytokine Enriched Natural Killer | ImmunityBio, Inc. | Platinum-resistant Ovarian Cancer | 05/27 | 05/27 | | |
NCT06040918: Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis |
|
|
| Completed | 1 | 10 | US | N-803 | ImmunityBio, Inc. | Healthy Subjects | 09/24 | 09/24 | | |
NCT04898543: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 50 | US | M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A) | ImmunityBio, Inc. | Metastatic Solid Tumor | 03/25 | 03/25 | | |
| Nguyen, Binh |
NCT05491915: The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain |
|
|
| Recruiting | N/A | 50 | US | SPRINT Peripheral Nerve Stimulation (PNS) System | SPR Therapeutics, Inc. | Cervicogenic Headache, Occipital Neuralgia | 08/27 | 08/27 | | |
| Pare, Laura |
| No trials found |
| Al-Ghazi, Muthana |
| No trials found |
| Evensen, Marc |
| No trials found |
| Burrow, Eldean |
| No trials found |
